288 related articles for article (PubMed ID: 15880743)
1. Neuronal vulnerability in mouse models of Huntington's disease: membrane channel protein changes.
Ariano MA; Wagle N; Grissell AE
J Neurosci Res; 2005 Jun; 80(5):634-45. PubMed ID: 15880743
[TBL] [Abstract][Full Text] [Related]
2. Striatal neurochemical changes in transgenic models of Huntington's disease.
Ariano MA; Aronin N; Difiglia M; Tagle DA; Sibley DR; Leavitt BR; Hayden MR; Levine MS
J Neurosci Res; 2002 Jun; 68(6):716-29. PubMed ID: 12111832
[TBL] [Abstract][Full Text] [Related]
3. Striatal potassium channel dysfunction in Huntington's disease transgenic mice.
Ariano MA; Cepeda C; Calvert CR; Flores-Hernández J; Hernández-Echeagaray E; Klapstein GJ; Chandler SH; Aronin N; DiFiglia M; Levine MS
J Neurophysiol; 2005 May; 93(5):2565-74. PubMed ID: 15625098
[TBL] [Abstract][Full Text] [Related]
4. Striatal spiny neurons and cholinergic interneurons express differential ionotropic glutamatergic responses and vulnerability: implications for ischemia and Huntington's disease.
Calabresi P; Centonze D; Pisani A; Sancesario G; Gubellini P; Marfia GA; Bernardi G
Ann Neurol; 1998 May; 43(5):586-97. PubMed ID: 9585352
[TBL] [Abstract][Full Text] [Related]
5. Mitigation of augmented extrasynaptic NMDAR signaling and apoptosis in cortico-striatal co-cultures from Huntington's disease mice.
Milnerwood AJ; Kaufman AM; Sepers MD; Gladding CM; Zhang L; Wang L; Fan J; Coquinco A; Qiao JY; Lee H; Wang YT; Cynader M; Raymond LA
Neurobiol Dis; 2012 Oct; 48(1):40-51. PubMed ID: 22668780
[TBL] [Abstract][Full Text] [Related]
6. Striatal modulation of cAMP-response-element-binding protein (CREB) after excitotoxic lesions: implications with neuronal vulnerability in Huntington's disease.
Giampà C; DeMarch Z; D'Angelo V; Morello M; Martorana A; Sancesario G; Bernardi G; Fusco FR
Eur J Neurosci; 2006 Jan; 23(1):11-20. PubMed ID: 16420411
[TBL] [Abstract][Full Text] [Related]
7. Cell type-specific localization of optineurin in the striatal neurons of mice: implications for neuronal vulnerability in Huntington's disease.
Okita S; Morigaki R; Koizumi H; Kaji R; Nagahiro S; Goto S
Neuroscience; 2012 Jan; 202():363-70. PubMed ID: 22155493
[TBL] [Abstract][Full Text] [Related]
8. Distinct expression of phosphorylated N-methyl-D-aspartate receptor NR1 subunits by projection neurons and interneurons in the striatum of normal and amphetamine-treated rats.
Liu Z; Mao L; Parelkar NK; Tang Q; Samdani S; Wang JQ
J Comp Neurol; 2004 Jun; 474(3):393-406. PubMed ID: 15174082
[TBL] [Abstract][Full Text] [Related]
9. Mice heterozygous for neurotrophin-3 display enhanced vulnerability to excitotoxicity in the striatum through increased expression of N-methyl-D-aspartate receptors.
Torres-Peraza J; Pezzi S; Canals JM; Gavaldà N; García-Martínez JM; Pérez-Navarro E; Alberch J
Neuroscience; 2007 Jan; 144(2):462-71. PubMed ID: 17081696
[TBL] [Abstract][Full Text] [Related]
10. Striatal neuronal apoptosis is preferentially enhanced by NMDA receptor activation in YAC transgenic mouse model of Huntington disease.
Shehadeh J; Fernandes HB; Zeron Mullins MM; Graham RK; Leavitt BR; Hayden MR; Raymond LA
Neurobiol Dis; 2006 Feb; 21(2):392-403. PubMed ID: 16165367
[TBL] [Abstract][Full Text] [Related]
11. Selective neuronal degeneration in Huntington's disease.
Cowan CM; Raymond LA
Curr Top Dev Biol; 2006; 75():25-71. PubMed ID: 16984809
[TBL] [Abstract][Full Text] [Related]
12. Striatal interneurons in Huntington's disease: selective increase in the density of calretinin-immunoreactive medium-sized neurons.
Cicchetti F; Parent A
Mov Disord; 1996 Nov; 11(6):619-26. PubMed ID: 8914086
[TBL] [Abstract][Full Text] [Related]
13. DNA microarray analysis of striatal gene expression in symptomatic transgenic Huntington's mice (R6/2) reveals neuroinflammation and insulin associations.
Crocker SF; Costain WJ; Robertson HA
Brain Res; 2006 May; 1088(1):176-86. PubMed ID: 16626669
[TBL] [Abstract][Full Text] [Related]
14. The fate of striatal dopaminergic neurons in Parkinson's disease and Huntington's chorea.
Huot P; Lévesque M; Parent A
Brain; 2007 Jan; 130(Pt 1):222-32. PubMed ID: 17142832
[TBL] [Abstract][Full Text] [Related]
15. Sodium channel beta4 subunit: down-regulation and possible involvement in neuritic degeneration in Huntington's disease transgenic mice.
Oyama F; Miyazaki H; Sakamoto N; Becquet C; Machida Y; Kaneko K; Uchikawa C; Suzuki T; Kurosawa M; Ikeda T; Tamaoka A; Sakurai T; Nukina N
J Neurochem; 2006 Jul; 98(2):518-29. PubMed ID: 16805843
[TBL] [Abstract][Full Text] [Related]
16. Diminished hippocalcin expression in Huntington's disease brain does not account for increased striatal neuron vulnerability as assessed in primary neurons.
Rudinskiy N; Kaneko YA; Beesen AA; Gokce O; Régulier E; Déglon N; Luthi-Carter R
J Neurochem; 2009 Oct; 111(2):460-72. PubMed ID: 19686238
[TBL] [Abstract][Full Text] [Related]
17. Phosphodiesterase type IV inhibition prevents sequestration of CREB binding protein, protects striatal parvalbumin interneurons and rescues motor deficits in the R6/2 mouse model of Huntington's disease.
Giampà C; Middei S; Patassini S; Borreca A; Marullo F; Laurenti D; Bernardi G; Ammassari-Teule M; Fusco FR
Eur J Neurosci; 2009 Mar; 29(5):902-10. PubMed ID: 19291221
[TBL] [Abstract][Full Text] [Related]
18. The fate of the large striatal interneurons expressing calretinin in Huntington's disease.
Massouh M; Wallman MJ; Pourcher E; Parent A
Neurosci Res; 2008 Dec; 62(4):216-24. PubMed ID: 18801393
[TBL] [Abstract][Full Text] [Related]
19. Changes in expression of N-methyl-D-aspartate receptor subunits occur early in the R6/2 mouse model of Huntington's disease.
Ali NJ; Levine MS
Dev Neurosci; 2006; 28(3):230-8. PubMed ID: 16679770
[TBL] [Abstract][Full Text] [Related]
20. N-methyl-D-aspartate (NMDA) receptor function and excitotoxicity in Huntington's disease.
Fan MM; Raymond LA
Prog Neurobiol; 2007 Apr; 81(5-6):272-93. PubMed ID: 17188796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
